Tradestie Institutional Equity Comparison Engine

QURE vs ELVN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ELVN Overall Edge

ELVN Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Enliven Therapeutics, Inc. Common Stock (ELVN) driven by superior Growth & Margin, Momentum & Technical while QURE counters with relative strength in Valuation, Options & Structure. Fundamentally, QURE trades at 27.9x Forward P/E with -994.0% operating margin (+40.4% YoY revenue) versus ELVN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, QURE sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against ELVN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner QURE
QURE 27.9x vs ELVN N/M Fwd P/E
Growth & Margin Winner ELVN
Op Margin -994.0% vs 0.0% ยท YoY +40.4% vs +0.0%
Momentum & Technical Winner ELVN
1Y -27.4% vs +134.5% ยท 52W Pos 31% vs 69%
Options & Structure Winner QURE
BREAKDOWN (<1st %ile IV) vs CONSOLIDATION (5th %ile IV)
QURE NASDAQ
uniQure N.V.
Pharmaceutical Preparations
$22.02
-7.52% 1D
Market Cap $1.7B
1M Return +1.1%
1Y Return -27.42%
Forward P/E 27.9x
Unified AI Score
48.9 / 100 HOLD
Tech 42.0 Fund 55.0 Flow 69.0 Mom 60.0
ELVN NASDAQ
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
1M Return +27.38%
1Y Return +134.53%
Forward P/E N/M
Unified AI Score
36.2 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: QURE -27.42% ELVN +134.53% Spread: +161.95 pp (ELVN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
QURE TTM Op. Margin: -994.0% ELVN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QURE vs ELVN. Trailing 12-month operating profitability (QURE -994.0% vs ELVN 0.0%) and valuation multiples (QURE 27.9x vs ELVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: QURE (4) vs ELVN (5)
Institutional Metric QURE ELVN Criterion Row Winner
Market Capitalization Scale $1.7B $3.6B Larger Scale ELVN
Trailing P/E Ratio Valuation 27.9x N/M Lower Multiple QURE
Forward P/E Ratio Valuation 27.9x N/M Lower Multiple QURE
Revenue Growth (YoY) Growth +40.4% +0.0% Higher Growth QURE
Operating Margin (TTM) Profitability -994.0% 0.0% Higher Margin ELVN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -89.0% -16.8% Higher ROE ELVN
52-Week Range Position Momentum 31% ($9โ€“$52) 69% ($15โ€“$62) Stronger Trend ELVN
Beta / 30D Volatility Risk Regime 0.80ฮฒ ยท 81% Vol 0.96ฮฒ ยท 60% Vol Lower Realized Risk ELVN
Unified Institutional Score Composite Signal 48.9 / 100 (HOLD) 36.2 / 100 (SELL) Higher Composite QURE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full QURE vs ELVN Buy Guide
QURE BREAKDOWN
102d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live QURE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ELVN CONSOLIDATION
59d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live ELVN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither QURE nor ELVN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.